Готові списки джерел за темами / Malaria vaccine Synthesis

Добірка наукової літератури з теми "Malaria vaccine Synthesis"

Автор: Grafiati
Опубліковано: 10 грудня 2022
Оновлено: 29 січня 2023

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Зміст

Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Malaria vaccine Synthesis".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Статті в журналах з теми "Malaria vaccine Synthesis"

1

Clemente, Marina, and Mariana G. Corigliano. "Overview of Plant-Made Vaccine Antigens against Malaria." Journal of Biomedicine and Biotechnology 2012 (2012): 1–8. http://dx.doi.org/10.1155/2012/206918.

Повний текст джерела
Анотація:
This paper is an overview of vaccine antigens against malaria produced in plants. Plant-based expression systems represent an interesting production platform due to their reduced manufacturing costs and high scalability. At present, differentPlasmodiumantigens and expression strategies have been optimized in plants. Furthermore, malaria antigens are one of the few examples of eukaryotic proteins with vaccine value expressed in plants, making plant-derived malaria antigens an interesting model to analyze. Up to now, malaria antigen expression in plants has allowed the complete synthesis of these vaccine antigens, which have been able to induce an active immune response in mice. Therefore, plant production platforms offer wonderful prospects for improving the access to malaria vaccines.
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Ballou, W. R., J. Blood, T. Chongsuphajaissidhi, D. M. Gordon, D. G. Heppner, D. E. Kyle, C. Luxemburger, et al. "Field trials of an asexual blood stage malaria vaccine: studies of the synthetic peptide polymer SPf66 in Thailand and the analytic plan for a phase IIb efficacy study." Parasitology 110, S1 (March 1995): S25—S36. http://dx.doi.org/10.1017/s0031182000001463.

Повний текст джерела
Анотація:
SummarySeveral years ago the Walter Reed Army Institute of Research (WRAIR) initiated an independent analysis of the candidate malaria blood stage vaccine SPf66. WRAIR contracted for the synthesis and formulation of SPf66 in United States Food and Drug Administration (FDA) inspected laboratories within the U.S., and in 1992, filed an Investigational New Drug (IND) application with the FDA. Preclinical studies indicated that the vaccine could be synthesized to meet its release specifications, and when adjuvanted with alum, was essentially equivalent to Colombian produced SPf66 in regards to immunogenicity in preclinical studies of rodents and primates, and in human volunteers in Phase I studies. The goal of these efforts was ultimately to conduct a Phase IIb field trial to determine the safety and efficacy of SPf66 produced under current Good Manufacturing Practices (cGMP). Such a trial is currently underway in a malaria endemic refugee camp along the Thai–Burmese border. Here we briefly describe the study and present the formal analytic plan that was submitted to regulatory authorities in the United States for analysis of the study results. We believe such independent confirmatory studies are an essential part of the vaccine development process and are required to provide important data regarding the safety and efficacy of candidate vaccines in diverse geographical regions, and as a means to assess their role in the context of broader malaria control programmes.
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Moysa, A. A., and E. F. Kolesanova. "Synthetic peptide vaccines." Biomeditsinskaya Khimiya 57, no. 1 (January 2011): 14–30. http://dx.doi.org/10.18097/pbmc20115701104.

Повний текст джерела
Анотація:
This review considers the stages of the development of synthetic peptide vaccines against infectious agents, novel approaches and technologies employed in this process, including bioinformatics, genomics, proteomics, large-scale peptide synthesis, high-throughput screening methods, the use of transgenic animals for modelling human infections. An important role for the development and selection of efficient adjuvants for peptide immunogens is noted. Examples of synthetic peptide vaccine developments against three infectious diseases (malaria, hepatitis C, and foot-and-mouth disease) are given.
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Olugbile, S., C. Kulangara, G. Bang, S. Bertholet, E. Suzarte, V. Villard, G. Frank, et al. "Vaccine Potentials of an Intrinsically Unstructured Fragment Derived from the Blood Stage-Associated Plasmodium falciparum Protein PFF0165c." Infection and Immunity 77, no. 12 (September 28, 2009): 5701–9. http://dx.doi.org/10.1128/iai.00652-09.

Повний текст джерела
Анотація:
ABSTRACT We have identified new malaria vaccine candidates through the combination of bioinformatics prediction of stable protein domains in the Plasmodium falciparum genome, chemical synthesis of polypeptides, in vitro biological functional assays, and association of an antigen-specific antibody response with protection against clinical malaria. Within the predicted open reading frame of P. falciparum hypothetical protein PFF0165c, several segments with low hydrophobic amino acid content, which are likely to be intrinsically unstructured, were identified. The synthetic peptide corresponding to one such segment (P27A) was well recognized by sera and peripheral blood mononuclear cells of adults living in different regions where malaria is endemic. High antibody titers were induced in different strains of mice and in rabbits immunized with the polypeptide formulated with different adjuvants. These antibodies recognized native epitopes in P. falciparum-infected erythrocytes, formed distinct bands in Western blots, and were inhibitory in an in vitro antibody-dependent cellular inhibition parasite-growth assay. The immunological properties of P27A, together with its low polymorphism and association with clinical protection from malaria in humans, warrant its further development as a malaria vaccine candidate.
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Chandrudu, Saranya, Mariusz Skwarczynski, David Pattinson, Simon H. Apte, Denise L. Doolan, and Istvan Toth. "Synthesis and immunological evaluation of peptide-based vaccine candidates against malaria." Biochemical Compounds 4, no. 1 (2016): 1. http://dx.doi.org/10.7243/2052-9341-4-1.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Joshi, Manju B., Albert A. Gam, Robert A. Boykins, Sanjai Kumar, John Sacci, Stephen L. Hoffman, Hira L. Nakhasi, and Richard T. Kenney. "Immunogenicity of Well-Characterized Synthetic Plasmodium falciparum Multiple Antigen Peptide Conjugates." Infection and Immunity 69, no. 8 (August 1, 2001): 4884–90. http://dx.doi.org/10.1128/iai.69.8.4884-4890.2001.

Повний текст джерела
Анотація:
ABSTRACT Given the emerging difficulties with malaria drug resistance and vector control, as well as the persistent lack of an effective vaccine, new malaria vaccine development strategies are needed. We used a novel methodology to synthesize and fully characterize multiple antigen peptide (MAP) conjugates containing protective epitopes fromPlasmodium falciparum and evaluated their immunogenicity in four different strains of mice. A di-epitope MAP (T3-T1) containing two T-cell epitopes of liver stage antigen-1 (LSA-1), a di-epitope MAP containing T-cell epitopes from LSA-1 and from merozoite surface protein-1, and a tri-epitope MAP (T3-CS-T1) containing T3-T1 and a potent B-cell epitope from the circumsporozoite protein central repeat region were tested in this study. Mice of all four strains produced peptide-specific antibodies; however, the magnitude of the humoral response indicated strong genetic restriction between the different strains of mice. Anti-MAP antibodies recognized stage-specific proteins on the malaria parasites in an immunofluorescence assay. In addition, serum from hybrid BALB/cJ × A/J CAF1 mice that had been immunized with the tri-epitope MAP T3-CS-T1 successfully inhibited the malaria sporozoite invasion of hepatoma cells in vitro. Spleen cells from immunized mice also showed a genetically restricted cellular immune response when stimulated with the immunogen in vitro. This study indicates that well-characterized MAPs combining solid-phase synthesis and conjugation chemistries are potent immunogens and that this approach can be utilized for the development of subunit vaccines.
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Hewitt, Michael C., Daniel A. Snyder, and Peter H. Seeberger. "Rapid Synthesis of a Glycosylphosphatidylinositol-Based Malaria Vaccine Using Automated Solid-Phase Oligosaccharide Synthesis." Journal of the American Chemical Society 124, no. 45 (November 2002): 13434–36. http://dx.doi.org/10.1021/ja027538k.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Kanoi, Bernard N., Hikaru Nagaoka, Masayuki Morita, Takafumi Tsuboi, and Eizo Takashima. "Leveraging the wheat germ cell-free protein synthesis system to accelerate malaria vaccine development." Parasitology International 80 (February 2021): 102224. http://dx.doi.org/10.1016/j.parint.2020.102224.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Kronenberger, Thales, Jasmin Lindner, Kamila A. Meissner, Flávia M. Zimbres, Monika A. Coronado, Frank M. Sauer, Isolmar Schettert, and Carsten Wrenger. "Vitamin B6-Dependent Enzymes in the Human Malaria ParasitePlasmodium falciparum: A Druggable Target?" BioMed Research International 2014 (2014): 1–11. http://dx.doi.org/10.1155/2014/108516.

Повний текст джерела
Анотація:
Malaria is a deadly infectious disease which affects millions of people each year in tropical regions. There is no effective vaccine available and the treatment is based on drugs which are currently facing an emergence of drug resistance and in this sense the search for new drug targets is indispensable. It is well established that vitamin biosynthetic pathways, such as the vitamin B6de novosynthesis present inPlasmodium, are excellent drug targets. The active form of vitamin B6, pyridoxal 5-phosphate, is, besides its antioxidative properties, a cofactor for a variety of essential enzymes present in the malaria parasite which includes the ornithine decarboxylase (ODC, synthesis of polyamines), the aspartate aminotransferase (AspAT, involved in the protein biosynthesis), and the serine hydroxymethyltransferase (SHMT, a key enzyme within the folate metabolism).
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Pfeiffer, Bernhard, Elisabetta Peduzzi, Kerstin Moehle, Rinaldo Zurbriggen, Reinhard Glück, Gerd Pluschke, and John A. Robinson. "A Virosome-Mimotope Approach to Synthetic Vaccine Design and Optimization: Synthesis, Conformation, and Immune Recognition of a Potential Malaria-Vaccine Candidate." Angewandte Chemie International Edition 42, no. 21 (May 30, 2003): 2368–71. http://dx.doi.org/10.1002/anie.200250348.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Більше джерел

Дисертації з теми "Malaria vaccine Synthesis"

1

Yepuri, Nageshwar Rao. "The design and synthesis of novel anti-malarial agents." Access electronically, 2004. http://www.library.uow.edu.au/adt-NWU/public/adt-NWU20050330.085201/index.html.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Hewitt, Michael Charles 1975. "Solution and solid-phase synthesis of potential carbohydrate vaccines for leishmaniasis and malaria." Thesis, Massachusetts Institute of Technology, 2002. http://hdl.handle.net/1721.1/27111.

Повний текст джерела
Анотація:
Thesis (Ph. D.)--Massachusetts Institute of Technology, Dept. of Chemistry, 2002.
Vita.
Includes bibliographical references.
The human disease leishmaniasis afflicts over 20 million people worldwide, and is caused by unicellular protozoan parasites. Cell surface carbohydrates are implicated in immune recognition of the parasite by host macrophages. The synthesis of a unique tetrasaccharide found on the parasite cell surface lipophosphoglycan is described. The synthetic material was used to create two novel immungens that are currently being evaluated in an animal model. New methods were also developed for an automated solid-phase synthesis that took a fraction of the time required for the solution-phase synthesis. Malaria kills over 2 million people per year, and is caused by protozoan parasites of the genus Plasmodium. Much of the morbidity and mortality associated with malaria is thought to be due to a toxin released in the host following red blood cell rupture. A glycosylphosphatidylinositol (GPI) anchor of parasite origin was recently identified, and had the properties of a toxin. The synthesis of a modified version of the malarial GPI both in solution and on solid-phase in an automated fashion is described. The synthetic material was attached to a carrier protein and used to immunize mice, who were substantially protected against all aspects of a subsequent challenge by malarial parasites. A new capping protocol for automated solid-phase synthesis is described. A novel fluorous silyl triflate was used to tag deletion sequences that could then be separated from the desired sequence by filtration through fluorous reverse-phase silica gel. Two trisaccharide sequences were synthesized both with and without fluorous capping to demonstrate the effectiveness of the capping protocol.
by Michael Charles Hewitt.
Ph.D.
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Brune, Karl Dietrich. "Engineering modular platforms for rapid vaccine development." Thesis, University of Oxford, 2016. https://ora.ox.ac.uk/objects/uuid:41d57165-6e7c-4ca7-8025-b5ec31794c8c.

Повний текст джерела
Анотація:
Vaccines have saved more lives than any other medical intervention. Recombinant vaccines provide unmatched safety profiles, but at the expense of reduced immunogenicity. Virus-like particles (VLPs) resemble viruses in size, shape and repetitive arrangement but are devoid of pathogenic genetic material and therefore safe. Poor immunogens can be rendered immunogenic by display on VLPs. Successfully decorating VLPs is still a major challenge. Genetic fusion or chemical modification is often time-consuming and can lead to misassembly or misfolding, which obstructs generation of the desired immune response. SpyCatcher is a genetically encodable protein, previously engineered to form a covalent isopeptide bond to its peptide-partner SpyTag. Presented in this thesis are SpyCatcher-VLPs, based on the fusion of SpyCatcher to the bacteriophage VLP AP205. SpyCatcher- VLPs can be conveniently conjugated with SpyTag fused antigens, simply by mixing. I demonstrate the modularity of this approach by covalently linking several complex, cysteine-rich malarial antigens to SpyCatcher-VLPs, such as the transmission-blocking antigen Pfs25 and the blood-stage antigen CIDR. A single administration of Pfs25-SpyTag conjugated to SpyCatcher-VLPs induced potent antibody generation against Pfs25, even in the absence of adjuvant. Anti-Pfs25 antibodies induced by this platform conveyed potent transmission-blocking activity in the mosquito vector. The thesis further demonstrates the feasibility of more complex Catcher-nanoparticle architectures. The previously engineered SnoopCatcher covalently reacts with SnoopTag peptide and is orthogonal to the SpyCatcher / SpyTag pair. IMX313 is an engineered chimera of the multimerization domain of chicken complement inhibitor C4-binding protein. This work describes fusion of SnoopCatcher and SpyCatcher to IMX313, which yields independently addressable Catcher-moieties on a single IMX313 nanoparticle. Display of two antigens on one particle may enable single-particle, multi-disease vaccines as well as multi-stage vaccines to tackle immune evasion of parasites. The platforms presented should accelerate and enhance vaccine development and may create opportunities for imaging and metabolic engineering.
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Steinbeis, Fridolin [Verfasser]. "Protective potential and immunological evaluation of synthetic Plasmodium GPI glycoconjugate vaccines against experimental cerebral malaria / Fridolin Steinbeis." Berlin : Medizinische Fakultät Charité - Universitätsmedizin Berlin, 2017. http://d-nb.info/1133492908/34.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.

Книги з теми "Malaria vaccine Synthesis"

1

Visweswara Rao, Pasupuleti, Balam Satheesh Krishna, and Mohammad Saffree Jeffree, eds. Coronaviruses Transmission, Frontliners, Nanotechnology and Economy. UMS Press, 2022. http://dx.doi.org/10.51200/coronavirusesdrraoums2021.

Повний текст джерела
Анотація:
Coronaviruses are the viruses which cause different types of diseases in humans and animals. They belong to Coronaviridae family. Coronaviruses have unique shape which consists of spiked rings and sometimes to deal with them is a tough task. They are the tiny organisms which can only be seen under the microscopes. Even though the corona viruses exist in nature since decades, however the seriousness is only seen with the pandemic SARS-CoV II or COVID-19. It has taken so many lives away and the loss of various businesses. Keeping in view these situations, the authors and editors try to bring few of the important aspects together and compiled this book. The transmissions occur through different means and the vaccines are under production by various giant companies. Second chapter deals with animals as sources of transmitting agents to spread corona virus. Up to date the Centre for Disease Control and Prevention (CDC) recognizes 7 species of coronaviruses that infect humans, with the earliest known species identified in the mid-1960s. The known human coronaviruses are 229E (alpha coronavirus), NL63 (alpha coronavirus), OC43 (beta coronavirus), HKU1 (beta coronavirus), MERS-CoV (causes Middle East Respiratory Syndrome, MERS), SARS-CoV (causes Severe Acute Respiratory Syndrome, SARS) and SARS-CoV-2 (causes the coronavirus disease also in 2019, also known as COVID-19). Third chapter dealt with risk assessment for front liners during COVID-19 pandemic and clearly explained about the risk assessment factors. Healthcare workers (HCWs) are on the frontline of treating patients infected with COVID-19. However, data related to its infection rate among HCWs are limited. Chapter 4 deals with the nanotechnology and its applications on viral diseases. Nanobiotechnology is science of nanoparticle synthesis by using biotechnological applications in biology, physics, engineering, drug delivery, diagnostics, and chemistry. The use of metal/ polymeric nanoparticles as drug delivery systems has become extensive in last two decades. The commercialization of developed novel nanoparticles/drug loaded polymeric nanoparticles delivery systems are required to eradicate virus with improved safety measures in the humans with affordable cost. Chapter 5 mainly focused on the impact of COVID -19 on China, Malaysia, Indonesia, and India. The outbreak of the Covid-19 pandemic is an unprecedented shock to the Emerging economies. The evidence reported in various studies indicates that epidemic disease impacts on a country's economy through several channels, including the health, transportation, agricultural and tourism sectors. In the chapter 6, the authors discussed the psychological response, ranges from adaptive to maladaptive spectrum. We wish to express our gratitude to all the authors and contributors from Malaysia, Indonesia, and India for readily accepting our invitation and timely contributions without any delay. We greatly appreciate their commitment. We also thank Universiti Malaysia Sabah and Universitas Abdurrab for the great collaboration and collaborative efforts.
Стилі APA, Harvard, Vancouver, ISO та ін.

Частини книг з теми "Malaria vaccine Synthesis"

1

Stocker, Bridget L., Alexandra Hölemann, and Peter H. Seeberger. "Automated Oligosaccharide Synthesis to Create Vaccines for Malaria and Other Parasites." In ACS Symposium Series, 137–62. Washington, DC: American Chemical Society, 2008. http://dx.doi.org/10.1021/bk-2008-0989.ch007.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Spetzler, J. C., C. Rao, and J. P. Tam. "A novel approach to a synthetic malaria vaccine using the multiple antigen peptide system." In Peptides, 750–52. Dordrecht: Springer Netherlands, 1994. http://dx.doi.org/10.1007/978-94-011-0683-2_249.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Etlinger, Howard M. "The Use of Recombinant Proteins and Synthetic Peptides in the Development of a Plasmodium Falciparum Malaria Vaccine." In Modern Vaccinology, 341–56. Boston, MA: Springer US, 1994. http://dx.doi.org/10.1007/978-1-4899-1450-7_18.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Nardin, Elizabeth. "Synthetic Peptides as Malaria Vaccines." In Malaria, 495–540. CRC Press, 1999. http://dx.doi.org/10.1201/b17000-21.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

"Synthetic Peptides as Malaria Vaccines." In Malaria, 509–54. CRC Press, 1999. http://dx.doi.org/10.1201/b17000-24.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Corradin, Giampietro, Nora Céspedes, Antonio Verdini, Andrey V. Kajava, Myriam Arévalo-Herrera, and Sócrates Herrera. "Malaria Vaccine Development Using Synthetic Peptides as a Technical Platform." In Synthetic Vaccines, 107–49. Elsevier, 2012. http://dx.doi.org/10.1016/b978-0-12-396548-6.00005-6.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.

Тези доповідей конференцій з теми "Malaria vaccine Synthesis"

1

Patarroyo, Manuel Elkin. "Different strategies towards the design of a synthetic subunit malaria vaccine." In Future Aspect in Peptide Chemistry - Ringberg Conference. Prague: Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, 1999. http://dx.doi.org/10.1135/css199901108.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Також вас можуть зацікавити розширені добірки на тему "Malaria vaccine Synthesis" для конкретних типів джерел:
Статті в журналах
Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!

До бібліографії